A5022621152- Multiple Myeloma Research and Treatments
- CAR-T cell therapy research
- Protein Degradation and Inhibitors
- Chronic Myeloid Leukemia Treatments
- Histone Deacetylase Inhibitors Research
- Monoclonal and Polyclonal Antibodies Research
- Acute Myeloid Leukemia Research
- Peptidase Inhibition and Analysis
- Biosimilars and Bioanalytical Methods
- Hematopoietic Stem Cell Transplantation
- Chronic Lymphocytic Leukemia Research
- COVID-19 Clinical Research Studies
- Actinomycetales infections and treatment
- Ubiquitin and proteasome pathways
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Pneumothorax, Barotrauma, Emphysema
- Synthesis and Biological Evaluation
- Nanoparticles: synthesis and applications
- Biomedical Ethics and Regulation
- Hemoglobinopathies and Related Disorders
- Cancer Mechanisms and Therapy
- Respiratory Support and Mechanisms
- Beetle Biology and Toxicology Studies
- SARS-CoV-2 and COVID-19 Research
University of California, San Francisco
2024-2025
Icahn School of Medicine at Mount Sinai
2018-2025
University of California System
2025
Mount Sinai Hospital
2024
Memorial Sloan Kettering Cancer Center
2021
Southern California Clinical and Translational Science Institute
2019
University of California, Los Angeles
2015-2018
T-cell redirection therapy using chimeric antigen receptor (CAR) T cells and bispecific antibodies (BiAbs) has shown promising efficacy in heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM), leading to the approval of 2 CAR products numerous BiAb trials. Data on outcomes after relapse following BiAbs are urgently required develop strategies for sequencing salvage therapies. We identified 58 progressing a trial at Mount Sinai Hospital. Progression-free survival (PFS)...
B-cell maturation antigen (BCMA)-targeting chimeric receptor T cells (CAR-Ts) used in multiple myeloma (MM) are rapidly becoming a mainstay the treatment of relapsed/refractory (R/R) disease, and CAR-T expansion after infusion has been shown to inform depth duration response (DoR), but measuring this process remains investigational. This multicenter study describes kinetics prognostic impact absolute lymphocyte count (ALC) first 15 days 156 patients with relapsed MM treated BCMA-targeting...
Nocardial infections have been rare after allogeneic hematopoietic stem cell transplantation (HSCT). We report 10 recent cases of late-onset nocardiosis (median time onset 508 days transplantation) primarily in patients on high doses corticosteroids for graft-versus-host disease. All had pulmonary infection caused by Nocardia species susceptible to trimethoprim-sulfamethoxazole (TMP-SMX). At diagnosis 8 were not receiving TMP-SMX prophylaxis Pneumocystis jiroveci pneumonia (PJP; 7...
To evaluate the association between pre-hospitalization antiplatelet medication use and COVID-19 disease severity.
Abstract Stem cell transplantation (SCT) has been an integral treatment modality for multiple myeloma (MM) decades. However, as standard‐of‐care therapies have improved, the benefit of SCT repeatedly called into question. This retrospective study evaluated association between in first line therapy (LOT) and outcomes patients with newly diagnosed (NDMM) United States. We included from a de‐identified electronic health record‐derived database who initiated front‐line MM January 1, 2016, 31,...
Filanesib is a first-in-class kinesin spindle protein inhibitor which demonstrated safety and encouraging activity in combination with bortezomib dexamethasone relapsed/refractory multiple myeloma preliminary analysis of dose-escalation phase results. This multicenter study included first to determine maximum tolerated dose two schedules filanesib, bortezomib, subsequent dose-expansion using the doses. In phase, 28 patients were evaluable for efficacy. The most common grade ≥3 adverse events...
7517 Background: Trials for NSCLC have increasingly targeted specific molecular abnormalities. This approach has led to approval of multiple drugs based on results in BioM populations prior completion randomized trials. As a result, many trials now require evaluation fresh biopsy enrollment. Implications potentially increased duration screening interpretation clinical outcomes not been completely explored. Methods: We reviewed charts patients (pts) with consented 26 between January 2012 and...
Abstract Introduction: Expansion of chimeric receptor antibody (CAR)-T cells after infusion has been described as important marker in multiple myeloma (MM); however, the phenomenon overt lymphocytosis not reported. We describe kinetics absolute lymphocyte count (ALC) BCMA CAR-T MM a depth response and progression-free survival (PFS). Methods: 158 patients (pts) were included (93 pts ciltacabtagene autoleucel (cilta-cel) 65 idecabtagene vicleucel (ide-cel) from three institutions. Baseline...